Gynecologic oncology最新文献

{"title":"Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer","authors":"Aya Bashi ,&nbsp;Katherine N. Penvose ,&nbsp;Jason D. Wright ,&nbsp;Stephanie V. Blank ,&nbsp;Benjamin B. Albright ,&nbsp;William D. Hazelton ,&nbsp;Emma Rossi ,&nbsp;Evan R. Myers ,&nbsp;Angeles Alvarez Secord ,&nbsp;Laura J. Havrilesky","doi":"10.1016/j.ygyno.2026.02.009","DOIUrl":"10.1016/j.ygyno.2026.02.009","url":null,"abstract":"<div><h3>Objective</h3><div>We sought to identify efficient tumor molecular profiling strategies for patients with newly diagnosed stage III–IVA endometrial cancer.</div></div><div><h3>Methods</h3><div>We constructed a decision tree model to compare molecular profiling strategies. We considered testing options of mismatch repair (MMR), p53, and HER2 immunohistochemistry (IHC), and next generation sequencing (NGS, assessing for MMR protein, <em>TP53</em> and <em>POLE</em> mutations). Strategies included (1) <u>MMR/p53</u>: MMR/p53 IHC at diagnosis, with HER2 IHC if p53 abnormal and NGS reserved for first progression/recurrence; (2) <u>Selective NGS</u>: MMR/p53 IHC at diagnosis, with immediate NGS and HER2 IHC if p53 abnormal, otherwise NGS at recurrence; (3) <u>Universal NGS</u>: NGS and HER2 IHC at diagnosis for all. Molecular subtype prevalence and six-year recurrence-free survival by subtype were derived from the GOG-0258 randomized trial. Outcomes included costs (2024 US$), timely NGS results (results available at recurrence/progression), and unnecessary NGS (NGS performed in patients who remained recurrence-free).</div></div><div><h3>Results</h3><div>Universal NGS resulted in unnecessary NGS in 57% of patients who remained recurrence-free, compared with 7% under the Selective NGS strategy and 0% with MMR/p53. MMR/p53 was the least costly strategy (mean cost $3772), followed by Selective NGS ($4186) and Universal NGS ($6250). Compared with MMR/p53, Selective NGS cost $2571 per additional timely NGS result, while Universal NGS cost $7600 per additional timely NGS result compared with Selective NGS.</div></div><div><h3>Conclusions</h3><div>Selective molecular profiling of newly diagnosed stage III-IVA endometrial cancers using MMR and p53 IHC with reflex to NGS for p53-abnormal tumors improves testing efficiency and reduces unnecessary NGS compared with universal upfront NGS testing.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 67-73"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer","authors":"Tina Yi Jin Hsieh ,&nbsp;Ting-Tai Yen ,&nbsp;Michele R. Hacker ,&nbsp;Joseph Dottino ,&nbsp;Katharine M. Esselen","doi":"10.1016/j.ygyno.2026.03.010","DOIUrl":"10.1016/j.ygyno.2026.03.010","url":null,"abstract":"<div><h3>Objective</h3><div>We examined whether the addition of GLP-1RA to progestin therapy reduced the risk of hysterectomy in patients with endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC) in the U.S. managed with fertility-sparing management.</div></div><div><h3>Methods</h3><div>Women ≤45 years old at EIN/EC diagnosis were identified in the TriNetX Research Collaborative Network (1/1/2017–12/01/2025). Patients initiating GLP-1 RA plus progestins (megestrol acetate, medroxyprogesterone acetate, or levonorgestrel-releasing intrauterine device) formed the GLP-1 RA + progestin group and were compared with the progestin-only group. Groups were 1:1 propensity-score matched (PSM) for demographics, BMI, HbA1c, type 2 diabetes, comorbidities, medication use, healthcare utilization, and EIN/EC. Patients were followed up for 6, 12, and 18 months from treatment initiation until the occurrence of hysterectomy; loss to follow-up; or December 1, 2025. Hazard ratios (HRs) with 95% confidence intervals (CI) were estimated using Cox proportional hazards regression. Analyses for subgroups, head-to-head comparisons were also performed.</div></div><div><h3>Results</h3><div>After 1:1 PSM (<em>n</em> = 432 in each group), hysterectomy occurred in 10.2% of the GLP-1RA + progestin group versus 23.4% in the matched progestin-only group (HR 0.41, 95% CI 0.29–0.58) at 18 months, with significant reductions observed as early as 6 months. This protective association was consistent across subgroups, including younger patients (&lt;40 years), EC diagnosis, progestin type (LNG-IUD or oral progestins), and GLP-1RA type (semaglutide or tirzepatide).</div></div><div><h3>Conclusion</h3><div>Adjunct GLP-1 receptor agonist therapy was associated with reduced hysterectomy risk in EIN and EC, supporting prospective fertility-sparing studies.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 23-29"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying ovarian cancer with AI analysis of abdominal CT scans","authors":"Katherine Sawaya ,&nbsp;Margot Maraghe ,&nbsp;Samantha Metzger ,&nbsp;Carolina Modena Heming ,&nbsp;Megan McDonald ,&nbsp;Vincent M. Wagner ,&nbsp;David P. Bender ,&nbsp;Michael J. Goodheart ,&nbsp;Jesus Gonzalez Bosquet","doi":"10.1016/j.ygyno.2026.01.774","DOIUrl":"10.1016/j.ygyno.2026.01.774","url":null,"abstract":"<div><h3>Background</h3><div>Epithelial ovarian cancer (EOC) has a high case-fatality rate, largely due to diagnosis at advanced stages and lack of effective screening tools. Conventional screening tools, like CA125 and ultrasound, have limited sensitivity and specificity. Advances in deep learning (DL) applied to medical imaging such as CT scans offer a promising avenue for improving early EOC detection.</div></div><div><h3>Objective</h3><div>To build, develop, and validate prediction models of EOC using deep machine learning (DL) to process and analyze abdominal-pelvic CT scans.</div></div><div><h3>Methods</h3><div>We performed a pilot case-control study to predict EOC using artificial intelligence (AI) methodology and abdominal-pelvic CT scans comparing EOC patients (cases, <em>N</em> = 355) to patients with histology-proven benign adnexal masses (controls, <em>N</em> = 213). CT images were converted to 3D NIFTI format and segmented using the ovseg pipeline. Multiple DL architectures were evaluated, including convolutional neural networks (CNNs) and vision transformers (ViTs). Model performance was assessed using area under the operating characteristic curve (AUC), accuracy, and precision. Model interpretability was evaluated using Gradient-weighted Class Activation Mapping (Grad-CAM). Radiomics-based models were constructed using PyRadiomics features and compared with DL models.</div></div><div><h3>Results</h3><div>Most of women had and advanced FIGO stage, 88%, and high grade histology, 92%. Exploratory analysis of different methods without segmentation (or masking) resulted in poor performances, with AUCs between 0.39 and 0.83. The best performing models were those trained with CNN architecture with masked images, with AUC of 0.92. Validation and testing performances for EOC prediction with PyRadiomics had AUCs of 0.74 and 0.66 respectively.</div></div><div><h3>Conclusions</h3><div>DL using segmented abdominal-pelvic CT scans, particularly CNN-based architecture, demonstrate strong potential for distinguishing EOC from benign pelvic masses. Further studies are needed to create accurate DL models for early EOC detection.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 30-37"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Society of Gynecologic Oncology Annual Meeting Special Issue","authors":"","doi":"10.1016/j.ygyno.2026.04.001","DOIUrl":"10.1016/j.ygyno.2026.04.001","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Page 1"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial","authors":"Bin Liu ,&nbsp;Jian Chen ,&nbsp;Lijun Chen ,&nbsp;Xiaoxiang Chen ,&nbsp;Yanhong Zhuo ,&nbsp;Linlin Yang ,&nbsp;Yuzhi Li ,&nbsp;Jie Lin ,&nbsp;Xinye Guo ,&nbsp;Yingtao Lin ,&nbsp;Tongyu Liu ,&nbsp;Jianping Zou ,&nbsp;Yu Jiang ,&nbsp;Yang Sun","doi":"10.1016/j.ygyno.2026.03.014","DOIUrl":"10.1016/j.ygyno.2026.03.014","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the interim efficacy and safety of cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with platinum-based chemotherapy as first-line treatment for patients with primary advanced or recurrent endometrial cancer (EC), with exploratory analyses by molecular subgroups.</div></div><div><h3>Methods</h3><div>This investigator-initiated, multicenter, open-label, single-arm phase II trial enrolled women aged 18–75 years with histologically confirmed FIGO stage III/IV or recurrent EC. Patients received cadonilimab (10 mg/kg intravenously every 3 weeks) combined with platinum-based chemotherapy, followed by cadonilimab maintenance. The primary endpoint was objective response rate (ORR) assessed per RECIST v1.1. Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Exploratory analyses were performed according to PD-L1 expression, mismatch repair (MMR) status, and molecular subtype. This interim analysis was conducted after 27 efficacy-evaluable patients reached the predefined PFS milestone.</div></div><div><h3>Results</h3><div>Among 27 patients, ORR was 74.1% (95% CI, 55.6%–87.3%), including one complete response (3.7%) and 19 partial responses (70.4%), with a DCR of 96.3%. Median time to response was 2.8 months, and median DoR was 17.8 months (95% CI, 8.8–not estimable). Median PFS was 10.5 months (95% CI, 8.2–not estimable), with a 12-month PFS rate of 49.6%. Median OS was not reached; the 12-month OS rate was 90.2%. ORR was generally consistent across subgroups, while patients with dMMR tumors showed a lower risk of disease progression compared with those with pMMR tumors. Treatment-related adverse events occurred in 77.8% of patients, predominantly grade 1–2; grade ≥ 3 events occurred in 18.5%, with no treatment-related deaths.</div></div><div><h3>Conclusions</h3><div>Cadonilimab combined with chemotherapy demonstrated clinically meaningful activity and manageable safety as first-line treatment for advanced or recurrent EC, supporting further investigation, particularly in molecularly defined populations.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 14-22"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGO 2026 annual meeting: Honors and Recognitions for Authors and Reviewers for 2025-2026","authors":"","doi":"10.1016/j.ygyno.2026.04.002","DOIUrl":"10.1016/j.ygyno.2026.04.002","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Page 2"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study","authors":"Els Van Nieuwenhuysen ,&nbsp;Ignace Vergote ,&nbsp;Leslie M. Randall ,&nbsp;Jacqueline Tromp ,&nbsp;Domenica Lorusso ,&nbsp;Roisin E. O’Cearbhaill ,&nbsp;Ingrid Boere ,&nbsp;Carmela Pisano ,&nbsp;Luis Manso Sanchez ,&nbsp;Susana Banerjee ,&nbsp;Dearbhaile C. Collins ,&nbsp;Michal Zikán ,&nbsp;Cara Mathews ,&nbsp;Jan Kümmel ,&nbsp;Bohuslav Melichar ,&nbsp;Amanda L. Jackson ,&nbsp;Kristine Madsen ,&nbsp;Christine Gennigens ,&nbsp;Nelleke Ottevanger ,&nbsp;Sharad Ghamande ,&nbsp;Bradley J. Monk","doi":"10.1016/j.ygyno.2026.02.008","DOIUrl":"10.1016/j.ygyno.2026.02.008","url":null,"abstract":"<div><h3>Objective</h3><div>Treatment options for recurrent or metastatic cervical cancer (r/mCC) remain limited. We evaluated the efficacy and safety of tisotumab vedotin (TV)–based combinations with standard agents in first-line (1L) and previously treated (second-line or later [2L+]) settings in r/mCC.</div></div><div><h3>Methods</h3><div>innovaTV 205/ENGOT-cx8/GOG-3024 (<span><span>NCT03786081</span><svg><path></path></svg></span>) was a multicenter, open-label phase 1b/2 study, which included dose-expansion arms of 1L TV + carboplatin (arm D), 1L/2L+ TV + pembrolizumab (arms E/F), and 1L TV + carboplatin + pembrolizumab ± bevacizumab (arm H). The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).</div></div><div><h3>Results</h3><div>As of October 15, 2025, 139 patients were enrolled in dose-expansion arms D (<em>n</em> = 33), E (n = 33), F (<em>n</em> = 35), and H (<em>n</em> = 38). Confirmed ORR (median DOR) was 54.5% (8.6 months), 40.6% (not reached), 35.3% (18.2 months), and 65.8% (13.3 months) in arms D–F and H, respectively. Median PFS was 6.9, 5.3, 5.6, and 10.6 months; median OS was 25.5, 30.7, 15.3, and 28.0 months. Grade ≥ 3 AEs related to any treatment component occurred in 72.7%, 45.5%, 48.6%, and 86.8% of patients; AEs leading to TV discontinuation occurred in 24.2%, 24.2%, 34.3%, and 55.3% of patients in arms D–F and H, respectively.</div></div><div><h3>Conclusion</h3><div>With ≥ 5 years of follow-up, TV doublet combinations demonstrated durable activity consistent with previous findings and encouraging long-term OS in 1L and 2L+ r/mCC, with no new safety signals. The 1L TV-based triplet/quadruplet regimen showed meaningful antitumor activity with expected toxicity.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 3-13"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends","authors":"Gabriel Levin ,&nbsp;Lucy Gilbert ,&nbsp;Robert L. Coleman ,&nbsp;Raanan Meyer ,&nbsp;Reitan Ribeiro ,&nbsp;Bradley J. Monk","doi":"10.1016/j.ygyno.2026.02.002","DOIUrl":"10.1016/j.ygyno.2026.02.002","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate gender- and geography-based differences in industry payments to U.S. gynecologic oncologists and to characterize temporal trends in payments across therapeutic classes.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional analysis of the Centers for Medicare &amp; Medicaid Services Open Payments database from 2018 to 2024. All physicians listed as gynecologic oncologists were included, with general payments aggregated per physician. Payments were analyzed by physician gender, geographic region, and state. Drug-related payments were mapped to therapeutic classes relevant to gynecologic oncology, and temporal trends were examined descriptively.</div></div><div><h3>Results</h3><div>Overall 75,382 industry payments totaling $33.4 million were made to 2063 gynecologic oncologists (55.9% females, and 44.1% males). Males were overrepresented among the top 100 total earners (74% vs. 26%; <em>p</em> &lt; .001). Compared with females, males received higher median total payments ($863 vs. $312), a greater number of payments (12 vs. 6), and higher mean single payments ($64 vs. $49; all <em>p</em> &lt; .001). Regionally, the South accrued the highest total payments ($11.3 M), whereas mean single payments were highest in the West ($390). Drugs and biologics comprised 63.5% of all payments, dominated by PARP inhibitors, which peaked in 2019 and declined thereafter, while payments related to antibody–drug conjugates, immune checkpoint inhibitors, and tyrosine kinase inhibitors increased steadily and constituted the majority by 2024.</div></div><div><h3>Conclusions</h3><div>Industry payments to gynecologic oncologists demonstrate persistent gender and geographic diffrences and reflect evolving therapeutic priorities within the field. Increased transparency and proactive efforts are needed to promote balanced access to industry-sponsored opportunities as novel treatments emerge.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 60-66"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACT-ON: Assisted cascade testing via outreach and navigation – Real-world experience with clinician-facilitated cascade testing","authors":"Emily S. Epstein ,&nbsp;Michelle Primiano ,&nbsp;Amanda Laterza Ozarowski ,&nbsp;Tina Karimaghaie ,&nbsp;Max Kirby ,&nbsp;Steve Lopez ,&nbsp;Jose Alejandro Rauh-Hain ,&nbsp;Roni Wilke ,&nbsp;Haley A. Moss ,&nbsp;Jesse Brewer ,&nbsp;Sarah R. Levi ,&nbsp;Taylor LaRosa ,&nbsp;Alissa Kalyan ,&nbsp;Ashley Llenas ,&nbsp;Susan Marchal ,&nbsp;Li Bing Song ,&nbsp;Muhammad Danyal Ahsan ,&nbsp;Ravi N. Sharaf ,&nbsp;Melissa K. Frey","doi":"10.1016/j.ygyno.2026.01.775","DOIUrl":"10.1016/j.ygyno.2026.01.775","url":null,"abstract":"<div><h3>Objectives</h3><div>Cascade genetic testing is a pragmatic, high-impact strategy for cancer prevention; however, under the current patient-mediated model, only one-third of relatives complete testing. Clinician-facilitated cascade testing represents a promising alternative, though questions remain regarding scalability and effectiveness in real-world settings. We aimed to evaluate the outcomes of a real-world, clinician-facilitated cascade testing program.</div></div><div><h3>Methods</h3><div>We implemented a clinician-facilitated cascade testing program to contact, educate, and facilitate genetic testing for at-risk relatives. Probands from gynecologic oncology and cancer genetics clinics provided consent for direct relative contact for education on cascade testing and assistance with access to local or direct-to-consumer genetic counseling and testing services. Relatives were recontacted at six months for follow-up.</div></div><div><h3>Results</h3><div>From May 2023 to July 2025, 103 probands (median age 40 years; 87% female) identified 139 at-risk relatives. Of these, 91 (65%) relatives were successfully contacted and educated about the familial pathogenic variant (median age 45 years; 59% female) and 80 (88%) requested assistance with cascade testing. At six-month follow-up, 41 (77%) of relatives reached had completed genetic testing. On a follow-up survey, 100% of respondents reported that navigation support was integral to accessing testing and 68% indicated they would have been unlikely to pursue testing without clinician support.</div></div><div><h3>Conclusions</h3><div>In a real-world setting, clinician-facilitated cascade testing successfully contacted two-thirds of at-risk relatives, the majority of whom requested assistance with testing. These findings demonstrate the potential of clinician-facilitated navigation to overcome limitations of patient-mediated approaches and offer a scalable, patient-centered strategy for cancer prevention.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 38-46"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer","authors":"Kersten Rothnie ,&nbsp;Emilie Tristano ,&nbsp;Mariuxi Diaz-Rodriguez ,&nbsp;Olga Filippova ,&nbsp;Gizelka David-West ,&nbsp;Joan Tymon-Rosario ,&nbsp;Jill Whyte ,&nbsp;Marina Frimer ,&nbsp;Tung Ming Leung ,&nbsp;Fidel Valea ,&nbsp;Jeannine Villella ,&nbsp;Elena Pereira","doi":"10.1016/j.ygyno.2026.02.013","DOIUrl":"10.1016/j.ygyno.2026.02.013","url":null,"abstract":"<div><h3>Objectives</h3><div>To demonstrate the detection of circulating human papillomavirus (HPV) DNA fragments can serve as a biomarker for presence of tumor and provide a universal, non-invasive tool for monitoring treatment response in HPV-related cervical cancers (CC).</div></div><div><h3>Methods</h3><div>A multi-site prospective study of HPV-positive high-grade cervical dysplasia (CIN2/3) and CC was conducted. Serum samples were collected pre-, during, and post-treatment. NavDx® (Naveris,Inc) digital droplet polymerase chain reaction testing was used to detect tumor tissue modified viral (TTMV)-HPV DNA. The expanded panel included 14 HPV subtypes. Sensitivity and specificity were calculated for the pre-treatment Score only. Scores were quantified for on-treatment timepoints and trends were compared against treatment response.</div></div><div><h3>Results</h3><div>80 patients were included in the analysis: 46 (57.5%) CC, 26 (32.5%) CIN2/3, 8 (10.0%) benign. TTMV-HPV DNA was undetectable in all CIN 2/3 and benign cases. For CC, 38 (82.6%) had primary disease and 8 (17.4%) recurrent. For primary CC, 28 (73.7%) had stage I/II and 10 (26.3%) stage III/IV. Specificity for TTMV-HPV DNA for CC detection was 100% (95% CI: 89.7%–100.0%) for all stages. Sensitivity was 39.2% (95% CI: 21.5–59.4%) for stage I/II, 90% (95% CI: 55.5–99.7%) for stage III/IV, and 62.5% (95% CI: 24.4–91.48%) at recurrence. Disease progression/persistence occurred in 7 patients with corresponding increased Scores.</div></div><div><h3>Conclusions</h3><div>TTMV-HPV DNA is a sensitive and specific biomarker for advanced CC, with Scores dynamically corresponding to treatment response, and has the potential to serve an unmet need as a universal biomarker for patients with HPV-related CC.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 47-52"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}